Education
About Us
Working with TipRanks
Follow Us
Rein Therapeutics (RNTX)
NASDAQ:RNTX
RNTX Stock Chart & Stats
$1.26
--
Market closed
$1.26
--
Day’s Range― - ―
52-Week Range$1.02 - $3.50
Previous CloseN/A
VolumeN/A
Average Volume (3M)228.95K
Market Cap
$32.07M
Enterprise Value$71.14M
Total Cash (Recent Filing)$4.05M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.42
Next Earnings
Apr 06, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding26,286,383
10 Day Avg. Volume262,542
30 Day Avg. Volume228,948
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap2.22
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.17
Forecast
1Y Price Target
$8.00Price Target Upside534.92% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical TrialsFDA lifted the full clinical hold on the U.S. Phase 2 RENEW trial, allowing the company to resume enrollment across ~20 U.S. sites.
FinancingSecured up to $21M in flexible non-dilutive and equity-based financing capacity to support operational runway for Phase 2.
Pipeline PotentialThe stock is fundamentally undervalued given the company’s potential best-in-class pipeline, which targets significant market opportunities lacking effective or tolerable treatments.
Bears Say
Rein Therapeutics News
RNTX FAQ
What was Rein Therapeutics’s price range in the past 12 months?
Rein Therapeutics lowest stock price was $1.02 and its highest was $3.50 in the past 12 months.
What is Rein Therapeutics’s market cap?
Rein Therapeutics’s market cap is $32.07M.
When is Rein Therapeutics’s upcoming earnings report date?
Rein Therapeutics’s upcoming earnings report date is Apr 06, 2026 which is in 84 days.
How were Rein Therapeutics’s earnings last quarter?
Rein Therapeutics released its earnings results on Nov 14, 2025. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.24 by $0.03.
Is Rein Therapeutics overvalued?
According to Wall Street analysts Rein Therapeutics’s price is currently Undervalued.
Does Rein Therapeutics pay dividends?
Rein Therapeutics does not currently pay dividends.
What is Rein Therapeutics’s EPS estimate?
Rein Therapeutics’s EPS estimate is -0.22.
How many shares outstanding does Rein Therapeutics have?
Rein Therapeutics has 26,286,383 shares outstanding.
What happened to Rein Therapeutics’s price movement after its last earnings report?
Rein Therapeutics reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.24. Following the earnings report the stock price went down -7.407%.
Which hedge fund is a major shareholder of Rein Therapeutics?
Currently, no hedge funds are holding shares in RNTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rein Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (534.92% Upside)
$8.00 (534.92% Upside)
Insider Transactions
Bought Shares
Worth $550.5K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.80%
12-Months-Change
Fundamentals
Return on Equity
-83.28%
Trailing 12-Months
Asset Growth
-48.47%
Trailing 12-Months
Company Description
Rein Therapeutics
Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.
RNTX Stock 12 Month Forecast
Average Price Target
$8.00
▲(534.92% Upside)
Technical Analysis
―
Kezar Life Sciences
―
Vivos Therapeutics
―
OnKure Therapeutics
―
Rani Therapeutics Holdings
―
Ownership Overview
7.15% Insiders
3.57% Mutual Funds
21.09% Other Institutional Investors
63.88% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---